Clinical Trial Update: Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the safety and preliminary efficacy of combining metformin, nelfinavir, and bortezomib in patients with relapsed and/or refractory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Nelfinavir (nelfinavir)
• metformin (metformin)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: COMPLETED